Lukas Greifenstein - Institute of Nuclear Chemistry, Johannes Gutenberg University

基本信息

浏览量：2

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 25 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Long-Term Safety and Survival Outcomes of [225Ac]ac-Psma (Prostate-Specific Membrane Antigen) and [225Ac]ac-/[177Lu]lu-psma (TANDEM) Radioligand Therapy (PRLT) in Metastatic Castration-Resistant Prostate Cancer

Elisabetta Perrone,Alessandro Giordano,Maria Lucia Calcagni,Lucia Leccisotti, Roberto Moretti,Aleksandr Eismant,Kriti Ghai, Tanay Parkar, Aditi Mishra,Axel Heidenreich,Ralph M. Wirtz, Joerg Mueller,Lukas Greifenstein, Richard P. Baum

CANCERSno. 3 (2025)

引用0浏览0WOS引用

First-in-human Study of an Optimized, Potential Kit-Type, SSTR Antagonist 68Ga-Data5m-lm4 in Patients with Metastatic Neuroendocrine Tumors

Jingjing Zhang,Lukas Greifenstein,Vivianne Jakobsson,Elcin Zan,Andre Klega,Frank Roesch,Christian Landvogt, Corinna Mueller, Richard P. Baum

THERANOSTICSno. 6 (2025): 2510-2522

引用0浏览0WOS引用

3BP-3940, a Highly Potent FAP-targeting Peptide for Theranostics - Production, Validation and First in Human Experience with Ga-68 and Lu-177

Lukas Greifenstein, Annika Gunkel,Aileen Hoehne,Frank Osterkamp,Christiane Smerling,Christian Landvogt, Corinna Mueller,Richard P. Baum

JOURNAL OF NUCLEAR MEDICINE (2024)

引用5浏览0WOS引用

Long-term Adverse Events and Survival of Patients with Neuroendocrine Neoplasms (NEN) Receiving Peptide Receptor Radioligand Therapy (PRRT) Using 225Ac-and 225Ac-/177Lu-labeled (TANDEM) Antagonist DOTA-LM3: A Retrospective Analysis

Elisabetta Perrone, Aditi Mishra,Aleksandr Eismant,Kriti Ghai,Lukas Greifenstein,Richard P. Baum

JOURNAL OF NUCLEAR MEDICINE (2024)

引用0浏览0引用

Radiomolecular Theranostics with Fibroblast-Activation-Protein Inhibitors and Peptides

Richard P. Baum,Emil Novruzov,Tianzhi Zhao,Lukas Greifenstein,Vivianne Jakobsson,Elisabetta Perrone, Aditi Mishra,Aleksandr Eismant,Kriti Ghai, Ortwin Klein, Bastian Jaeschke, Daniel Benz-Zils,Jens Cardinale,Yuriko Mori,Frederik L. Giesel,Jingjing Zhang

Seminars in Nuclear Medicine（2024）

引用2浏览0WOS引用

Fibroblast Activating Protein (Fap)-Targeted Radiopeptide Therapy Using 177Lu-, 225Ac- and 90Y-Labeled 3BP-3940 in Diverse Advanced Solid Tumors: First-in-Humans Results

Richard P. Baum,Vivianne Jakobsson,Aleksandr Eismant,Carsten Kramer,Lukas Greifenstein,Aditi Mishra,Andre Klega,Christian Landvogt, Corinna Mueller,Elcin Zan,Jingjing Zhang

JOURNAL OF NUCLEAR MEDICINE (2023)

引用0浏览0引用

First-in-human Study of an Optimized, Kit-type, SSTR Antagonist 68Ga-Data5m-lm4 in Patients with Metastatic Neuroendocrine Tumors

Jingjing Zhang,Lukas Greifenstein,Vivianne Jakobsson,Carsten Kramer,Elcin Zan,Andre Klega,Frank Roesch,Christian Landvogt, Corinna Mueller,Richard P. Baum

JOURNAL OF NUCLEAR MEDICINE (2023)

引用0浏览0引用

First-in-human Study of a Novel Radiolabeled Fibroblast Activating Protein (Fap)-Targeted Peptide 68Ga-Fap-3bp-3940 for PET/CT Imaging in Patients with Solid Tumors

Vivianne Jakobsson,Jingjing Zhang,Lukas Greifenstein, Juncheng Huang,Xiaoyuan Chen,Richard P. Baum

JOURNAL OF NUCLEAR MEDICINE (2023)

引用0浏览0引用

From Automated Synthesis to in Vivo Application in Multiple Types of Cancer—Clinical Results with [68Ga]ga-Data5m.sa.fapi

Lukas Greifenstein, Carsten S. Kramer,Euy Sung Moon,Frank Roesch,Andre Klega,Christian Landvogt, Corinna Muller,Richard P. Baum

Pharmaceuticalsno. 8 (2022): 1000-1000

引用15浏览0WOS引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn